"No co-authors for this commentary"
This follows the Commission's August 30 approval of teriflunomide (Aubagio).
"MSGene samples studies that have investigated genetic markers for association with risk for MS. Whenever independent studies have looked at the same marker, we combine the evidence across studies using… Read"
Dear All, We are an NPO raising founds to open the first MS centre in South Africa, part of the idea is based on research that can take place in SA. the two basics idea behind are: 1.
An "MS patient?"
An "MS sufferer?"
A "person with MS?"
An iatrophic disease (in some circles) caused by the administration of chlioquinol. Patients exhibit symptoms very similar to MS and have not been exposed to chlioquinol. Nor do they exhibit the lesions of the brain.
Peter Stys acknowledges that overwhelming evidence supports the traditional view of multiple sclerosis (MS) as an autoimmune inflammatory disorder, where T cells wrongly attack the myelin sheathing of neurons and damage the underlying axons.